Johnson DN, et al. - In the present study, the researchers sought to analyze BRAF^V600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). For this analysis, they assessed for BRAF^V600E mutation using mutation-specific BRAF (VE1) antibody immunohistochemistry (BRAFVE) as part of an immunomorphologic tumor panel, often including HBME1, for follicular-patterned lesions with nuclear atypia. It was observed that BRAFVE used in conjunction with routine sampling of follicular-patterned tumors was a beneficial diagnostic adjuvant.